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consistently associated with measures of function and disability. Most
closely associated with function measures were: pain affecting sleep,
for WOMAC function; pain catastrophizing, for Late Life basic function,
chair stand time, and disability; and pain after 20 m walk, for Late Life
advanced function. These ﬁndings suggest that different aspects of the
pain experience in knee OA may have unique relationships with function
and disability. Ultimately, speciﬁc multidisciplinary attention to aspects
such as the impact of pain on sleep and pain catastrophizing may be
a more meaningful approach for the person with painful knee OA, and
potentially have greater impact on function and disability over time.
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Purpose: Better understanding of patients’ perceptions of osteoarthritis
(OA) severity can improve disease management. However, in clinical
practice, categorizing patients as having mild, moderate, or severe OA is
not straightforward.
Purpose: To evaluate the association of patient-reported OA severity
with other patient-reported outcomes in a European population using
the Adelphi Disease Speciﬁc Programme for OA (OA DSP VII, 2008).
Methods: OA severity was rated by patients based on the question “How
bad would you say your arthritis is now?” with potential responses
of “mild,” “moderate,” and “severe.” Other patient-reported outcomes
included; a pain visual analogue scale (0 = no pain, 100 = worst
possible pain); questions on activities of daily living (1 = no difﬁculty,
2 = some difﬁculty, 3 = much difﬁculty, 4 = unable to do); and the
EuroQol health status instrument (EQ-5D). Data on productivity were
captured using the Work Productivity and Activity Impairment scale
(WPAI). Associations between OA severity and other outcomes were
evaluated using descriptive and regression analyses.
Results: Data were available from 1739 patients (63.1% female, mean age
64 years) from France, Germany, Italy, Spain, and the United Kingdom.
OA severity was rated as mild, moderate and severe by 24.5%, 56.4%,
and 19.2% of the patients, respectively. There was an overall association
between patient-rated OA severity and age (p < 0.05). Greater patient-
reported OA severity was associated with higher pain scores; 28.3, 49.9,
and 69.2 for mild, moderate and severe OA, respectively (p < 0.05 for
pairwise comparisons). As patient-reported OA severity increased, so did
functional impairment as indicated by greater difﬁculty in performing 9
basic and 3 instrumental activities of daily living. After adjustment for
gender, the difﬁculty score was greater than 1 at each OA severity level
for every item of functional ability (lower bounds of the 95% conﬁdence
intervals were greater than 1); the greatest difﬁculty was observed
among patients who reported severe OA. Pairwise comparisons between
OA severity levels showed that differences in functional abilities were
statistically signiﬁcant (p < 0.05). Decreases in patient-reported health
status with increasing OA severity were also observed on the EQ-5D
health state VAS, and the health state index; 0.77, 0.62, and 0.30 for
mild, moderate, and severe OA, respectively (p < 0.0001 for all pairwise
comparisons). Among the 425 patients who were employed, the percent
of OA-related impairment of work and activity increased at greater OA
severity levels after adjusting for age and gender; higher costs resulting
from lost productivity were also observed with increasing OA severity
(p < 0.0001 for pairwise comparisons).
Conclusions: Patient-reported OA severity was associated with other
patient-reported outcomes, including productivity, and these outcomes
were most impacted in patients with severe OA. This method provides
an accurate and tangible assessment of patient’s perceptions of their
disease, and may be of beneﬁt in the clinical setting when choosing
treatment options for management of OA.
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PAIN MEDICATION TREATMENT AND JOINT REPLACEMENT SURGERY
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Purpose: Osteoarthritis (OA) is characterized by joint pain, stiffness,
and inﬂammation and can be associated with a signiﬁcant number
of comorbid conditions. In this retrospective longitudinal study, we
estimated the rate of hip and knee replacement surgery in patients
with OA and characterized joint replacement, pain medication treatment
patterns, and concomitant gastroprotective agent (GPA) use.
Methods: Data were enrollment information and medical and pharmacy
claims data from a large, national US health plan. The study population
was adult (age ≥18 years) commercial health plan enrollees newly
diagnosed with OA during the identiﬁcation period 1/1/2000–4/30/2009.
Patients had ≥2 medical claims with primary OA diagnoses (ICD-9-CM
715.xx, 721.0, 721.2, 721.3, 721.90) ≥30 days apart in the identiﬁcation
period; the index date was the date of the ﬁrst OA diagnosis. Patients
had 1 year of pre-index continuous enrollment with no chronic use of
NSAIDs, COX-2 inhibitors (coxibs), or oral opioids, and ≥1 year of post-
index enrollment. Outcomes included hip and knee replacement surgery
and pain medication use. Demographics, comorbidities, and Charlson
Comorbidity Index (CCI) score were measured. Data were analyzed
descriptively.
Results: Of 193,829 newly diagnosed patients with OA, 57% were
female and 43% were male. Patients whose ﬁrst observed chronic pain
medication use (index pain medications) were strong opioids appeared to
have a higher mean CCI score, 1.16, compared with those with NSAIDs,
coxibs, and weak opioid index pain medications (0.53–0.83). Patients
in the youngest (18–44) and oldest (75+) age groups appeared to be
more likely to have an opioid (35.7% and 34.9% respectively) as their
index pain medication compared with patients in the middle age groups
(45–54 yrs: 24.5%, 55–64 yrs: 19.9%, 65–74 yrs: 24.0%). The incident
rates of hip or knee replacement per person-year appeared to be higher
for those patients with opioids as their index pain medications (0.0663,
weak opioids; 0.0801, strong opioids; 0.0464, NSAIDS; 0.0548, coxibs).
The mean time from index pain medication to ANY joint replacement
appeared shorter for patients whose index pain medications were opioids
(106 days, weak opioids; 28 days, strong opioids; 320 days, nonselective
NSAIDs; 479 days, coxibs). Only 18% of patients prescribed NSAIDs were
co-prescribed a GPA.
Conclusions: The data from this study indicate speciﬁc patterns of
relationships between the index diagnosis of OA, joint replacement, pain
medication treatment, age, and concomitant GPA use. These data may
be important in reﬁning contemporary treatment guidelines, educating
physicians in appropriate care paths, and may warrant exploration of
potential unmet needs in the management of chronic pain in OA.
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Costa1, B. Rocha1, N. Oreiro2, C. Ferna´ndez-Lo´pez2, C. Ruiz-Romero1,
F.J. Blanco1. 1Osteoarticular and Aging Res. Lab., Proteomics Unit-Associated
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Purpose: Osteoarthritis (OA) is a degenerative joint disease that is
characterized by cartilage destruction and bone changes, occasionally
accompanied by synovial inﬂammation. A major objective for OA research
is the conceptualization and development of early diagnostic strategies.
The discovery of protein biomarker panels for early diagnosis, therapeutic
purposes and management in several diseases is an area of interest
in medicine. In the present work we have quantitatively screened
differential proteins in sera and cartilage from patients suffering OA
at diverse stages. To attain this objective, a quantitative proteomics
approach has been followed, which is based on peptide differential
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labelling with iTRAQ reagents and subsequent multidimensional LC-
MS/MS analysis.
Methods: 150 serum samples were obtained from OA patients at
different stages of the disease (grade II, grade IV and control donors)
and were grouped in pools to reduce interindividual variability. The
top twenty most abundant proteins in crude serum ﬂuids were
removed by afﬁnity chromatography using the immunodepletion column
ProteoPrep® 20. Cartilage samples were obtained from OA patients
undergoing joint replacement and normal donors without history of
joint disease. They were extracted with Urea 6M, 2% SDS using a
mixer Mill MM 200 (Retsch). Proteins were quantiﬁed, digested with
trypsin and differentially labelled with isobaric tags using iTRAQ. The
peptide mixture was separated by two dimensional LC coupled to MALDI-
TOF/TOF mass spectrometry. Identiﬁcation and relative quantiﬁcation of
the proteins were performed using ProteinPilot 3.0 software.
Results: Protein proﬁles between the OA patients (early or late) and
healthy controls were compared, leading to the identiﬁcation of 349
proteins. 28 proteins that were altered in OA with statistical signiﬁcance
and more than 1 peptide: 18 of them were increased (OA:Control >1.3,
p < 0.05) and 10 decreased (OA:Control <0.7, p < 0.05). 263 proteins were
identiﬁed in cartilage samples and 59 proteins were quantiﬁed with a
signiﬁcative p-value in OA patients compared to control. The quantiﬁed
proteins of cartilage and serum are involved mainly in biological
functions as extracellular organization, skeletal system development,
cell adhesion, apoptosis, defence and inﬂammatory response. In both
cases it was found that the majority of proteins belonging to the
extracellular matrix region. Identiﬁcation and quantiﬁcation of some
of these proteins both in serum and cartilage from OA patients indicate
their potential biomarker value for the pathology. We detected in both
samples the alteration of proteins such as cartilage oligomeric matrix
protein, lumican, complement factor D or thrombospondin-1, which
were found to be increased in OA, whereas the cytoplasmic actin was
decreased. Finally, a number of other proteins were identiﬁed as altered
either in cartilage (thus increasing our knowledge of OA pathogenesis)
or in serum (which have also potential biomarker value).
Conclusions: In summary, we have identiﬁed for the ﬁrst time a panel
of novel OA protein biomarkers present in serum and cartilage from
human patients by a proteomic approach. The speciﬁcity and selectivity
of these candidates should be veriﬁed in order to develop new molecular
diagnosis or prognosis tests for OA.
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DIFFERENCE GEL ELECTROPHORESIS ANALYSIS OF CARTILAGE
DEGRADATION IN A MOUSE MODEL OF OSTEOARTHRITIS IDENTIFIES
CHANGES IN KEY MOLECULAR PROCESSES
M.D. Gardiner1, L. Gatto2, H. Nagase1. 1Imperial Coll. London, London,
United Kingdom; 2Univ. of Cambridge, Cambridge, United Kingdom
Purpose: The protein proﬁle of cartilage during the initiation and
progression of osteoarthritis (OA) is likely to reﬂect the key early events
in the disease pathogenesis. Studying OA progression using human
cartilage is challenging owing to the difﬁculty in acquiring tissue. The
surgically induced destabilisation of the medial meniscus (DMM) mouse
model provides genetically homogenous cartilage at any disease stage.
Proteomic comparison of diseased and control cartilage identiﬁes protein
changes occurring in early OA.
Methods: The DMM mouse model was used to study the changes in
protein proﬁle of mouse knee articular cartilage during OA. A new
microdissection technique enabled targeted collection of pure mouse
articular cartilage from the medial tibial plateau. Three pooled biological
samples extracted from DMM and control knee joints at 2, 4 and 8 weeks
were compared using difference gel electrophoresis (DIGE). Differentially
expressed spots were identiﬁed by pair wise comparison of normalised
spot intensities from control and OA gels. Protein identiﬁcation from gel
spots was performed by tandemmass spectrometry. Histological sections
were used to assess cartilage degradation. Immunohistochemistry and
real-time RT-PCR were used to further investigate some of the protein
changes.
Results: There were no statistically signiﬁcant differences between DMM
and control cartilage at 2 and 4 weeks. Thirty-nine spots out of 1584
(2.5%) were statistically signiﬁcantly altered in abundance at 8 weeks
following DMM surgery. Thirteen distinct proteins from 26 spots were
increased in DMM cartilage and 5 distinct proteins from 13 spots were
decreased. Small leucine-rich repeat proteins, including biglycan, and
ﬁbromodulin, were signiﬁcantly increased in both protein abundance
and gene expression. Gelsolin, a regulator of the actin cytoskeleton,
protein disulﬁde isomerase A3, ﬁbrinogen beta chain and transitional
endoplasmic reticulum ATPase were also increased. A number of proteins
involved in energy production had an altered abundance; pyruvate
kinase, b-enolase and aconitate hydratase were decreased in abundance,
glycogen phosphorylase was increased.
Conclusions: Application of a new microdissection technique enabled
analysis of the protein proﬁle of pure mouse articular cartilage during
OA progression. This technique can be used to isolate and analyse other
joint tissues. The changes identiﬁed in OA cartilage at eight weeks
were consistent with alterations in energy production, the cytoskeleton
and cell stress. In addition, the greatly increased abundance of SLRPs
adds weight to the importance of these molecules in maintaining
cartilage homeostasis. Their roles extend beyond structural interactions
to encompass important signalling functions.
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Purpose: One of the most widely used compounds in the management of
patients with osteoarthritis (OA) is chondroitin sulfate (CS). The aim of
this work is to study drug modes of action, side-effects, and toxicity
of 3 different CS compounds using two complementary proteomic
approaches.
Methods: Chondrocytes were obtained from 3 OA patients undergoing
joint replacement. The study was approved by the local Ethics
Committee. Proteins expression analysis was carried out using DIGE
(Differential In Gel Electrophoresis) and SILAC (Stable Isotope Labeling
with Amino acids in Cell culture) techniques. In both cases OA
chondrocytes were treated with 200mg/mL of each brand of CS for
48 hours. For DIGE analysis, proteins samples from control and treated
cells were labeled with Cy3 or Cy5 dyes, mixed by pairs and co-
resolved by two-dimensional gel electrophoresis using a pool of all
samples labeled with Cy2 as internal standard. Quantitative image
analysis was performed using Same Spots software. The spots of interest
were analyzed by mass spectrometry (MALDI-MS). Protein identiﬁcation
was carried out by database search (MASCOT). For secretome analysis
by SILAC, cell-conditioned media from isotope-labeled (treated) and
unlabeled (untrated) samples were mixed 1:1, resolved by mono-
dimensional gel electrophoresis, and digested with trypsin. Separation
and analysis of peptides mixtures was performed by nanoﬂow liquid
chromatography coupled off-line to MALDI-MS. In this case protein
identiﬁcation and quantiﬁcation was carried out with Protein Pilot
software.
Results: We examined around 1500 protein spots that were present
in the 6 DIGE gels. We found 46 spots differentially expressed in
our conditions: 27 modulated by CS1, 4 by CS2 and 15 by CS3. We
didn’t observed qualitative changes in the treated cells. We could
identify 28 of the altered spots, corresponding to 18 different proteins.
CS1 strongly modulated mitochondrial superoxide dismutase (SOD2), a
protein previously described by our group as decreased in OA cartilage.
The SILAC experiment allowed us to identify 96 different proteins in
the CS1 secretome, 95 in CS2 and 104 in CS3. CS1 modulated the
expression of 21 proteins: 15 resulted upregulated and 6 downregulated.
CS2 modulated 13 proteins: 5 upregulated and 8 downregulated. Finally
CS3 modulated 9 proteins: 8 upregulated and only 1 downregulated. Each
one of the studied compounds induces a characteristic protein proﬁle
in OA chondrocytes cultures. In the case of CS1 more than 60% of the
altered proteins are speciﬁcally modulated only in this condition. The
same occurs with CS3, while most of the proteins modulated by CS2 are
in common with CS1 and CS3. Despite the highest number of proteins
modulated by CS1, as revealed by DIGE and SILAC experiments, and the
increased expression of SOD2, as above mentioned, some of them are
catabolic or inﬂammatory factors like interstitial collagenase (MMP1),
stromelysin-1 (MMP3) and pentraxin-related protein (PTX3).
